Question follow-through · 112238

Tourette's Syndrome: Diagnosis and Medical Treatments

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the availability of diagnostic and treatment pathways for Tourette syndrome across Integrated Care Boards; and for what reason Tourette syndrome has not b

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
10 Feb 2026
Target answer date
12 Feb 2026
Answer
18 Feb 2026 · 8 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

  1. 10 Feb 2026

    Question tabled

    To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the availability of diagnostic and treatment pathways for Tourette syndrome across Integrated Care Boards; and for what reason Tourette syndrome has not b

  2. 12 Feb 2026

    Target answer date

    Date supplied by the official written-questions record.

  3. 18 Feb 2026

    Answer published

    Integrated care boards (ICBs) are responsible for assessing local population need and commissioning appropriate diagnostic and treatment pathways for neurological conditions, including Tourette syndrome. While the Department has not undertaken a national ...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

No later same-department questions indexed.

This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.